Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific director transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific increase in the notional allocation of American Depositary Shares (ADSs) within the US Retirement Savings Plan due to a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: May 10, 2013.
- Notification Date: May 13, 2013.
- Instrument: GSK American Depositary Shares (ADSs).
- Price: $51.62 per ADS.
- Parties Involved: Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Volume: An increase of 4 ADSs in the notional allocation.
- Context: Result of a revaluation of the cash element within the US Retirement Savings Plan.